Cardiovascular complications of diabetes: recent insights in pathophysiology and therapeutics

References

• Zoungas S, Patel A. Cardiovascular outcomes in Type 2 diabetes: the impact of preventative therapies. Ann. NY Acad. Sci.1212, 29–40 (2010).
   PubMed Web of Science ®Google Scholar
• Thomas JE, Foody JM. The pathophysiology of cardiovascular disease in diabetes mellitus and the future of therapy. J. Cardiometab. Syndr.2(2), 108–113 (2007).
   PubMedGoogle Scholar
• Aryangat AV, Gerich JE. Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. Vasc. Health Risk Manag.6, 145–155 (2010).
   PubMedGoogle Scholar
• Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J. Am. Coll. Cardiol.55(13), 1310–1317 (2010).
   PubMed Web of Science ®Google Scholar
• Rivellese AA, Riccardi G, Vaccaro O. Cardiovascular risk in women with diabetes. Nutr. Metab. Cardiovasc. Dis.20(6), 474–480 (2010).
   PubMed Web of Science ®Google Scholar
• Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes and cardiovascular events. Diabetes Care33(6), 1389–1394 (2010).
   PubMed Web of Science ®Google Scholar
• Ariza MA, Vimalananda VG, Rosenzweig JL. The economic consequences of diabetes and cardiovascular disease in the United States. Rev. Endocr. Metab. Disord.11(1), 1–10 (2010).
   PubMedGoogle Scholar
• AHA. American Heart Association. Heart disease and stroke statistics – 2005 update. American Heart Association, TX, USA (2006).
   Google Scholar
• Mazzone T. Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data. Circulation122(21), 2201–2211 (2010).
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial – clinical implications. Clin. Chem.57(2), 261–263 (2011).
   PubMedGoogle Scholar
• Cannon CP. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications. Am. J. Cardiol.102(12A), 5L–9L (2008).
   Google Scholar
• Laakso M. Lipid disorders in Type 2 diabetes. Endocrinol. Nutr.56(Suppl. 4), 43–45 (2009).
   PubMedGoogle Scholar
• Schwartz SL. Diabetes and dyslipidaemia. Diabetes Obes. Metab.8(4), 355–364 (2006).
   PubMed Web of Science ®Google Scholar
• Ali YS, Linton MF, Fazio S. Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia. Curr. Opin. Endocrinol. Diabetes Obes.15(2), 142–146 (2008).
   PubMedGoogle Scholar
• Dunn FL. Management of dyslipidemia in people with Type 2 diabetes mellitus. Rev. Endocr. Metab. Disord.11(1), 41–51 (2010).
   PubMed Web of Science ®Google Scholar
• Rudkowska I. Fish oils for cardiovascular disease: impact on diabetes. Maturitas67(1), 25–28 (2010).
   PubMedGoogle Scholar
• Cannon CP. Combination therapy in the management of mixed dyslipidaemia. J. Intern. Med.263(4), 353–365 (2008).
   PubMed Web of Science ®Google Scholar
• Bell DS, Al Badarin F, O’Keefe JH Jr. Therapies for diabetic dyslipidemia. Diabetes Obes. Metab.13(4), 313–325 (2011).
   PubMedGoogle Scholar
• Mathieu P, Lemieux I, Despres JP. Obesity, inflammation, and cardiovascular risk. Clin. Pharmacol. Ther.87(4), 407–416 (2010).
   PubMed Web of Science ®Google Scholar
• Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Despres JP. Visceral obesity and the heart. Int. J. Biochem. Cell. Biol.40(5), 821–836 (2008).
   PubMed Web of Science ®Google Scholar
• Wheeler GL, Shi R, Beck SR et al. Pericardial and visceral adipose tissues measured volumetrically with computed tomography are highly associated in Type 2 diabetic families. Invest. Radiol.40(2), 97–101 (2005).
   PubMedGoogle Scholar
• Iacobellis G, Ribaudo MC, Assael F et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J. Clin. Endocrinol. Metab.88(11), 5163–5168 (2003).
   PubMed Web of Science ®Google Scholar
• Mazurek T, Zhang L, Zalewski A et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation108(20), 2460–2466 (2003).
   PubMed Web of Science ®Google Scholar
• Hsueh W, Abel ED, Breslow JL et al. Recipes for creating animal models of diabetic cardiovascular disease. Circ. Res.100(10), 1415–1427 (2007).
   PubMed Web of Science ®Google Scholar
• Renard CB, Kramer F, Johansson F et al. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J. Clin. Invest.114(5), 659–668 (2004).
   PubMed Web of Science ®Google Scholar
• Goldberg IJ. Why does diabetes increase atherosclerosis? I don’t know! J. Clin. Invest.114(5), 613–615 (2004).
   PubMed Web of Science ®Google Scholar
• Somwar R, Fang X, Sweeney G. Models of Type 2 diabetes. Drug Discovery Today2(3), 183–189 (2005).
   Google Scholar
• Fazio S, Linton MF. Mouse models of hyperlipidemia and atherosclerosis. Front. Biosci.6, D515–D525 (2001).
   Google Scholar
• Veniant MM, Withycombe S, Young SG. Lipoprotein size and atherosclerosis susceptibility in ApoE(-/-) and Ldlr(-/-) mice. Arterioscler. Thromb. Vasc. Biol.21(10), 1567–1570 (2001).
   PubMed Web of Science ®Google Scholar
• Veniant MM, Zlot CH, Walzem RL et al. Lipoprotein clearance mechanisms in LDL receptor-deficient ‘Apo-B48-only’ and ‘Apo-B100-only’ mice. J. Clin. Invest.102(8), 1559–1568 (1998).
   PubMed Web of Science ®Google Scholar
• Leppanen P, Koota S, Kholova I et al. Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice. Circulation112(9), 1347–1352 (2005).
   PubMed Web of Science ®Google Scholar
• Fazio S, Babaev VR, Burleigh ME, Major AS, Hasty AH, Linton MF. Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice. J. Lipid Res.43(10), 1602–1609 (2002).
   PubMedGoogle Scholar
• Tsutsumi Y, Losordo DW. Double face of VEGF. Circulation112(9), 1248–1250 (2005).
   PubMedGoogle Scholar
• Lavigne C, Marette A, Jacques H. Cod and soy proteins compared with casein improve glucose tolerance and insulin sensitivity in rats. Am. J. Physiol. Endocrinol. Metab.278(3), E491–E500 (2000).
   PubMed Web of Science ®Google Scholar
• Tremblay F, Lavigne C, Jacques H, Marette A. Dietary cod protein restores insulin-induced activation of phosphatidylinositol 3-kinase/Akt and GLUT4 translocation to the T-tubules in skeletal muscle of high-fat-fed obese rats. Diabetes52(1), 29–37 (2003).
   PubMed Web of Science ®Google Scholar
• Khamzina L, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology146(3), 1473–1481 (2005).
   PubMed Web of Science ®Google Scholar
• Ilany J, Bilan PJ, Kapur S et al. Overexpression of Rad in muscle worsens diet-induced insulin resistance and glucose intolerance and lowers plasma triglyceride level. Proc. Natl Acad. Sci. USA103(12), 4481–4486 (2006).
   PubMed Web of Science ®Google Scholar
• Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat. Med.7(10), 1138–1143 (2001).
   PubMed Web of Science ®Google Scholar
• Collins AR, Meehan WP, Kintscher U et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol.21(3), 365–371 (2001).
   PubMed Web of Science ®Google Scholar
• Towler DA, Bidder M, Latifi T, Coleman T, Semenkovich CF. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J. Biol. Chem.273(46), 30427–30434 (1998).
   PubMedGoogle Scholar
• Heinonen SE, Leppanen P, Kholova I et al. Increased atherosclerotic lesion calcification in a novel mouse model combining insulin resistance, hyperglycemia, and hypercholesterolemia. Circ. Res.101(10), 1058–1067 (2007).
   PubMedGoogle Scholar
• Devedjian JC, George M, Casellas A et al. Transgenic mice overexpressing insulin-like growth factor-II in β cells develop Type 2 diabetes. J. Clin. Invest.105(6), 731–740 (2000).
   PubMed Web of Science ®Google Scholar
• Duff CJ, Hooper NM. PCSK9: an emerging target for treatment of hypercholesterolemia. Expert Opin. Ther. Targets15(2), 157–168 (2011).
   PubMed Web of Science ®Google Scholar
• Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem.279(48), 50630–50638 (2004).
   PubMed Web of Science ®Google Scholar
• Ni YG, Condra JH, Orsatti L et al. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J. Biol. Chem.285(17), 12882–12891 (2010).
   PubMed Web of Science ®Google Scholar
• Davignon J, Dubuc G, Seidah NG. The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr. Atheroscler. Rep.12(5), 308–315 (2010).
   PubMed Web of Science ®Google Scholar
• Marian AJ. PCSK9 as a therapeutic target in atherosclerosis. Curr. Atheroscler. Rep.12(3), 151–154 (2010).
   PubMedGoogle Scholar
• Chan JC, Piper DE, Cao Q et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl Acad. Sci. USA106(24), 9820–9825 (2009).
   PubMed Web of Science ®Google Scholar
• Ni YG, Di Marco S, Condra JH et al. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J. Lipid Res.52(1), 78–86 (2011).
   PubMed Web of Science ®Google Scholar
• Costet P, Hoffmann MM, Cariou B, Guyomarc’h Delasalle B, Konrad T, Winkler K. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis212(1), 246–251 (2010).
   PubMed Web of Science ®Google Scholar
• Ason B, Tep S, Davis HR Jr. et al. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. J. Lipid Res.52(4), 679–687 (2011).
   PubMed Web of Science ®Google Scholar
• Montecucco F, Mach F. Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin. Immunopathol.31(1), 127–142 (2009).
   PubMedGoogle Scholar
• Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann. NY Acad. Sci.1212, E1–E19 (2010).
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Cardiovascular benefits of bariatric surgery in morbidly obese patients. Obes. Rev12(7), 515–524 (2011).
   PubMed Web of Science ®Google Scholar
• Xu A, Wang Y, Lam KS, Vanhoutte PM. Vascular actions of adipokines molecular mechanisms and therapeutic implications. Adv. Pharmacol.60, 229–255 (2010).
   PubMedGoogle Scholar
• Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int. J. Obes.32(Suppl. 7), S13–S18 (2008).
   PubMed Web of Science ®Google Scholar
• Okamoto Y. Adiponectin provides cardiovascular protection in metabolic syndrome. Cardiol. Res. Pract.2011, 313179 (2011).
   PubMedGoogle Scholar
• Ohashi K, Ouchi N, Matsuzawa Y. Adiponectin and hypertension. Am. J. Hypertens.24(3), 263–269 (2010).
   PubMedGoogle Scholar
• Shibata R, Sato K, Pimentel DR et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med.11(10), 1096–1103 (2005).
   PubMed Web of Science ®Google Scholar
• Shibata R, Izumiya Y, Sato K et al. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J. Mol. Cell. Cardiol.42(6), 1065–1074 (2007).
   PubMed Web of Science ®Google Scholar
• Holland WL, Miller RA, Wang ZV et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med.17(1), 55–63 (2011).
   PubMed Web of Science ®Google Scholar
• Debinski M, Buszman PP, Milewski K et al. Intracoronary adiponectin at reperfusion reduces infarct size in a porcine myocardial infarction model. Int. J. Mol. Med.27(6), 775–781 (2011).
   PubMedGoogle Scholar
• Shibata R, Ouchi N, Ito M et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med.10(12), 1384–1389 (2004).
   PubMed Web of Science ®Google Scholar
• Palanivel R, Fang X, Park M et al. Globular and full-length forms of adiponectin mediate specific changes in glucose and fatty acid uptake and metabolism in cardiomyocytes. Cardiovasc. Res.75(1), 148–157 (2007).
   PubMedGoogle Scholar
• Ganguly R, Schram K, Fang X et al. Adiponectin increases LPL activity via RhoA/ROCK-mediated actin remodelling in adult rat cardiomyocytes. Endocrinology152(1), 247–254 (2010).
   PubMedGoogle Scholar
• Fang X, Palanivel R, Cresser J et al. An APPL1–AMPK signaling axis mediates beneficial metabolic effects of adiponectin in the heart. Am. J. Physiol. Endocrinol. Metab.299(5), E721–E729 (2010).
   PubMed Web of Science ®Google Scholar
• Antonopoulos AS, Lee R, Margaritis M, Antoniades C. Adiponectin as a regulator of vascular redox state: therapeutic implications. Recent Pat. Cardiovasc. Drug Discov.6(2), 78–88 (2011).
   PubMedGoogle Scholar
• Nagasawa H, Yokota C, Toyoda K, Ito A, Minematsu K. High level of plasma adiponectin in acute stroke patients is associated with stroke mortality. J. Neurol. Sci.304(1–2), 102–106 (2011).
   PubMed Web of Science ®Google Scholar
• Liu Y, Retnakaran R, Hanley A, Tungtrongchitr R, Shaw C, Sweeney G. Total and high molecular weight but not trimeric or hexameric forms of adiponectin correlate with markers of the metabolic syndrome and liver injury in Thai subjects. J. Clin. Endocrinol. Metab.92(11), 4313–4318 (2007).
   PubMed Web of Science ®Google Scholar
• Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol. Sci.30(5), 234–239 (2009).
   PubMed Web of Science ®Google Scholar
• Salmenniemi U, Ruotsalainen E, Pihlajamaki J et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation110(25), 3842–3848 (2004).
   PubMed Web of Science ®Google Scholar
• Cote M, Mauriege P, Bergeron J et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J. Clin. Endocrinol. Metab.90(3), 1434–1439 (2005).
   PubMed Web of Science ®Google Scholar
• Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care20(4), 537–544 (1997).
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med.344(18), 1343–1350 (2001).
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med.346(6), 393–403 (2002).
   PubMed Web of Science ®Google Scholar
• Ratner R, Goldberg R, Haffner S et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care28(4), 888–894 (2005).
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Cote M, Matias I et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia52(2), 213–217 (2009).
   PubMed Web of Science ®Google Scholar
• Fedor D, Kelley DS. Prevention of insulin resistance by n-3 polyunsaturated fatty acids. Curr. Opin. Clin. Nutr. Metab. Care12(2), 138–146 (2009).
   PubMed Web of Science ®Google Scholar
• Harris WS, Mozaffarian D, Rimm E et al. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation119(6), 902–907 (2009).
   PubMed Web of Science ®Google Scholar
• Ramsden CE, Hibbeln JR, Majchrzak SF, Davis JM. n-6 fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials. Br. J. Nutr.104(11), 1586–1600 (2010).
   PubMed Web of Science ®Google Scholar
• Kurukulasuriya LR, Sowers JR. Therapies for Type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Cardiovasc. Diabetol.9, 45 (2010).
   PubMed Web of Science ®Google Scholar
• Graham MJ, Lemonidis KM, Whipple CP et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res.48(4), 763–767 (2007).
   PubMed Web of Science ®Google Scholar
• Frank-Kamenetsky M, Grefhorst A, Anderson NN et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl Acad. Sci. USA105(33), 11915–11920 (2008).
   PubMed Web of Science ®Google Scholar
• Felts AS. Molecule of the month. TREDAPTIVE (nicotinic acid/laropiprant): a new lipid-modifying therapy for the treatment of LDL-C, HDL-C and triglycerides. Curr. Top. Med. Chem.8(14), 1310 (2008).
   PubMedGoogle Scholar
• Hochtl T, Farhan S, Wojta J, Huber K. New anticoagulant agents in acute coronary syndromes. Heart97(3), 244–252 (2011).
   PubMed Web of Science ®Google Scholar
• Koo MH, Nawarskas JJ, Frishman WH. Prasugrel: a new antiplatelet drug for the prevention and treatment of cardiovascular disease. Cardiol. Rev.16(6), 314–318 (2008).
   PubMedGoogle Scholar
• Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.361(11), 1045–1057 (2009).
   PubMed Web of Science ®Google Scholar
• James S, Akerblom A, Cannon CP et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am. Heart J.157(4), 599–605 (2009).
   PubMed Web of Science ®Google Scholar
• Gu J, Noe A, Chandra P et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J. Clin. Pharmacol.50(4), 401–414 (2010).
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet375(9722), 1255–1266 (2010).
   PubMed Web of Science ®Google Scholar
• Patel N, Hegele RA. Mipomersen as a potential adjunctive therapy for hypercholesterolemia. Expert. Opin. Pharmacother.11(15), 2569–2572 (2010).
   PubMed Web of Science ®Google Scholar
• Verge D, Lopez X. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in Type 2 diabetes. Curr. Diabetes Rev.6(4), 191–200 (2010).
   PubMedGoogle Scholar
• Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M. Cardiovascular comorbidities of Type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. Am. J. Med.124(1 Suppl.), S35–S53 (2011).
   Web of Science ®Google Scholar
• King A. Coronary heart disease: new hope for CETP inhibitors. Nat. Rev. Cardiol.8(1), 5 (2011).
   PubMedGoogle Scholar
• Davidson MH. Update on inhibition. J. Clin. Lipidol.4(5), 394–398 (2010).
   PubMed Web of Science ®Google Scholar
• Bain JR, Stevens RD, Wenner BR, Ilkayeva O, Muoio DM, Newgard CB. Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes58(11), 2429–2443 (2009).
   PubMed Web of Science ®Google Scholar
• Lewis GD, Asnani A, Gerszten RE. Application of metabolomics to cardiovascular biomarker and pathway discovery. J. Am. Coll. Cardiol.52(2), 117–123 (2008).
   PubMed Web of Science ®Google Scholar
• Giovane A, Balestrieri A, Napoli C. New insights into cardiovascular and lipid metabolomics. J. Cell. Biochem.105(3), 648–654 (2008).
   PubMed Web of Science ®Google Scholar
• Charansonney OL, Despres JP. Disease prevention – should we target obesity or sedentary lifestyle? Nat. Rev. Cardiol.7(8), 468–472 (2010).
   PubMed Web of Science ®Google Scholar